logo
Salmonella outbreak in US: Know symptoms, causes and how to protect yourself

Salmonella outbreak in US: Know symptoms, causes and how to protect yourself

A recent Salmonella outbreak linked to eggs has sickened at least 79 people across seven US states, with 21 of them hospitalized. The majority of cases, 63, were reported in California, prompting a major recall of 1.7 million brown cage-free and organic eggs by California-based August Egg Company. On June 6, the Centers for Disease Control and Prevention (CDC) issued a public health warning after investigating cases reported between February and May 2025. According to the CDC and FDA, most affected individuals had eaten eggs or egg-based dishes before falling ill. Salmonella is a common cause of food poisoning that affects the intestinal tract, leading to symptoms like stomach cramps, diarrhea, and fever. Know its symptoms, causes and safety tips to prevent it.
Salmonella is a type of bacteria that causes food poisoning, known as Salmonella infection or salmonellosis. It spreads through contaminated food or water and is a common cause of stomach illness. According to the Centers for Disease Control and Prevention (CDC), over a million people in the US get infected, and around 420 deaths are reported each year. 'Once your body catches this bacteria, Salmonella attacks the lining of the intestines, leading to symptoms like diarrhea, stomach cramps, and sometimes fever,' explains Dr Sanket Mankad, Infectious Diseases Physician. While most people recover without treatment, it can be serious for young children, older adults, and those with weak immunity.
Salmonella spreads through contaminated food, water, and contact with infected animals or people.
Chicken is a major source of Salmonella. The CDC says 1 in 25 chicken packages may carry it. Undercooked chicken or contact with raw juices can spread the bacteria, increasing the risk of food poisoning.
Yes, Salmonella is contagious. It can spread from infected people or pets through unwashed hands, especially after using the bathroom or while sick. Touching contaminated surfaces or food can also pass the bacteria to others, causing infection.
According to the CDC, common symptoms of Salmonella infection include:
'These symptoms usually appear 12 to 96 hours after exposure but can take up to a week,' suggests Dr Mankad. Most people recover at home within 3 to 7 days without treatment. However, if symptoms persist beyond a week or if you notice blood in your stool, consult a doctor.
To avoid getting infected with Salmonella, follow these simple tips:
Stay updated to avoid getting infected.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bharat Biotech in-licences GSK's Shigella vaccine
Bharat Biotech in-licences GSK's Shigella vaccine

Time of India

timean hour ago

  • Time of India

Bharat Biotech in-licences GSK's Shigella vaccine

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development Shigella vaccine candidate, altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, a severe form of bacterial diarrhoea that largely affects children aged below five years in low- and middle-income countries. While GSK has already conducted Phase I and II trials in Europe and Africa, Bharat Biotech will take up further development with Phase III clinical trials, regulatory advancement, and large-scale manufacturing, the Hyderabad-based vaccine maker said on Thursday. As part of the agreement, GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalised modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. "The in-licensed candidate, altSonflex1-2-3, already showed encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response," Bharat Biotech said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Toulouse: Nous recherchons des personnes pour tester les nouvelles aides auditives HearPro En savoir plus Undo "Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals," it added. Bharat Biotech Executive Chairman Dr Krishna Ella said: "With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment." He pointed out that Bharat Biotech already has a significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. In 2021, GSK had inked a product transfer agreement for the world's first malaria vaccine, RTS,S, with Bharat Biotech. Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .

Bharat Biotech in-licences GSK's Shigella vaccine candidate
Bharat Biotech in-licences GSK's Shigella vaccine candidate

Time of India

time5 hours ago

  • Time of India

Bharat Biotech in-licences GSK's Shigella vaccine candidate

HYDERABAD: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licenced pharma giant GSK's Shigella vaccine candidate -- altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, which is a severe form of bacterial diarrhoea that largely affects children aged five years and below in low- and middle-income countries. While GSK has already conducted Phase-I and II trials in Europe and Africa, Bharat Biotech will be taking up further development with Phase-III clinical trials, regulatory advancement and large-scale manufacturing, Bharat Biotech said on Thursday. As part of the agreement, GSK will continue its support to the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalized modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. 'The in-licensed candidate, altSonflex1-2-3, has already shown encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response,' the Hyderabad-based vaccine maker said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it better to shower in the morning or at night? Here's what a microbiologist says CNA Read More Undo 'Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals,' it added. Bharat Biotech executive chairman Dr Krishna Ella said: 'With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment.' He pointed out that the addition of this vaccine candidate to its portfolio will strengthen Bharat Biotech's already significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. GSK already has an established relationship with BBIL, after it signed a product transfer agreement for the world's first malaria vaccine, RTS,S, to the Hyderabad-based company in 2021. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now

Neurotech and brain data: New frontier of privacy concerns
Neurotech and brain data: New frontier of privacy concerns

Hindustan Times

time6 hours ago

  • Hindustan Times

Neurotech and brain data: New frontier of privacy concerns

Consumer neurotechnology is no longer confined to sci-fi or academic labs. Thanks to AI advancements and shrinking chip sizes, devices that read brain activity, like EEG headsets, mood-tracking earbuds, and brain-controlled gaming accessories are entering the mainstream. Since 2011, over 130 startups have jumped into the consumer neurotech space. These tools, often embedded in wearables, promise productivity boosts, mental health insights, and immersive control over AR/VR environments. Tech giants like Apple and Snap are already exploring brain-computer interfaces (BCIs) for future headsets that could respond to mental states in real time. How Neurotech Works—And why It's risky EEG-based devices dominate this landscape, powering nearly 65% of consumer neurotech products. They track brainwave patterns linked to emotions, focus, and engagement levels. That may sound harmless until you realise this data could be mined to predict behaviours, preferences, or even political leanings. Imagine hyper-targeted ads based not on clicks, but on neural spikes. Or worse, cognitive surveillance, where employers or governments monitor attention levels, emotional stress, or signs of dissent. Cyberattacks targeting BCIs could introduce 'mental hacks', altering thought patterns or inducing confusion and distress. As one expert puts it, 'Brain data reveals thoughts before they're consciously expressed.' Regulatory gaps and urgent challenges The legal protections around all this? Alarmingly thin. While medical neurotech is regulated (MRIs or brain implants), consumer-grade EEG headsets fall into a grey zone. In the U.S., the FDA only monitors medical devices. State laws in places like California and Colorado require user consent for neural data use, but there's little enforcement. Internationally, concerns are mounting: China has tested neurotech in workplaces to track employee fatigue, while neuromarketing firms tap EEG feedback to fine-tune advertisements. 'Neural data could be weaponized for psychological warfare or blackmail.' Path forward So what now? We need clear federal laws that define how brain data can be collected, stored, and shared. Users should know exactly what's being tracked and who has access to it. Neural data must be encrypted, just like financial or medical records. Most importantly, the public must be made aware of what 'brain transparency' really means. Because the future of privacy may no longer be in your hands, but in your head. First Published Date: 12 Jun, 21:23 IST

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store